Media coverage about OpGen (NASDAQ:OPGN) has been trending somewhat negative recently, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. OpGen earned a media sentiment score of -0.03 on AlphaOne’s scale. AlphaOne also gave headlines about the medical research company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have impacted Alpha One Sentiment’s rankings:

Shares of OpGen (NASDAQ:OPGN) traded down 1.584% on Monday, reaching $0.994. The company’s stock had a trading volume of 155,807 shares. The stock’s market cap is $27.21 million. The firm’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.15. OpGen has a 12 month low of $0.87 and a 12 month high of $4.65.

Several research analysts have commented on the company. Zacks Investment Research downgraded OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 18th. HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of OpGen in a research note on Tuesday, February 28th.

WARNING: “OpGen (OPGN) Given Daily News Sentiment Score of -0.03” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/01/opgen-opgn-given-daily-news-sentiment-score-of-0-03.html.

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

5 Day Chart for NASDAQ:OPGN

Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.